Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Current Leases: 2011-2024

Historic Current Leases for Adma Biologics (ADMA) over the last 10 years, with Dec 2024 value amounting to $1.2 million.

  • Adma Biologics' Current Leases rose 8.80% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 8.80%. This contributed to the annual value of $1.2 million for FY2024, which is 16.56% up from last year.
  • Latest data reveals that Adma Biologics reported Current Leases of $1.2 million as of FY2024, which was up 16.56% from $1.0 million recorded in FY2023.
  • Adma Biologics' 5-year Current Leases high stood at $1.2 million for FY2024, and its period low was $365,682 during FY2020.
  • For the 3-year period, Adma Biologics' Current Leases averaged around $1.1 million, with its median value being $1.0 million (2023).
  • Data for Adma Biologics' Current Leases shows a peak YoY soared of 61.64% (in 2021) over the last 5 years.
  • Over the past 5 years, Adma Biologics' Current Leases (Yearly) stood at $365,682 in 2020, then skyrocketed by 61.64% to $591,084 in 2021, then surged by 53.11% to $905,000 in 2022, then climbed by 15.47% to $1.0 million in 2023, then grew by 16.56% to $1.2 million in 2024.